Business, energy, technology, markets and global industry news from Business News Today

Incyte Corporation

PharmaDeviceNews Incyte Corporation
A patient receives hospital-based infusion therapy as Australia’s PBS listing of Minjuvi expands access to a chemotherapy-free immunotherapy combination for adults with relapsed or refractory follicular lymphoma. Representative image.
Pharma & Biotech

Incyte’s Minjuvi gains Australian reimbursement after TGA follicular lymphoma registration

Australia has listed Minjuvi on the PBS for relapsed follicular lymphoma. See what the inMIND data and access terms mean.

Read More
Pfizer’s positive Phase 3 LITFULO results in nonsegmental vitiligo have strengthened the treatment’s global regulatory prospects, while detailed efficacy, safety and durability data remain key to its clinical and commercial outlook. Representative image.
Pharma & Biotech

Pfizer’s LITFULO cleared a major Phase 3 hurdle in vitiligo, but the missing numbers could decide its future

Pfizer’s Phase 3 LITFULO vitiligo results strengthen its filing case, but dose, safety and durability details remain decisive.

Read More
Incyte’s ESMO 2026 oncology programme will spotlight investigational treatments targeting pancreatic, colorectal and ovarian cancers. Representative image.
Pharma & Biotech

Why Incyte’s ESMO 2026 oncology readouts matter for its expanding Phase 3 pipeline

Incyte’s ESMO 2026 programme puts three investigational cancer assets under scrutiny across pancreatic, colorectal and ovarian tumours.

Read More
Incyte’s acquisition of Vega Therapeutics adds the Phase 3 monoclonal antibody VGA039 to its hematology pipeline, strengthening its strategy in von Willebrand disease treatment. Representative image.
Pharma & Biotech

Incyte closes $2bn Vega Therapeutics deal as VGA039 reshapes VWD strategy

Incyte has acquired Vega Therapeutics and Phase 3 VWD antibody VGA039. Explore the clinical promise, deal strategy and risks ahead.

Read More
Representative image showing blood cancer clinical research and treatment review, reflecting Incyte’s tafasitamab frontMIND trial update in high-risk diffuse large B-cell lymphoma.
Pharma & Biotech

Is Incyte’s tafasitamab regimen strong enough to challenge first-line DLBCL standards?

Find out how Incyte’s tafasitamab data could reshape first-line high-risk DLBCL treatment after frontMIND’s EHA 2026 readout.

Read More
Representative image: Hematology researchers review blood analysis data as Incyte Corporation’s INCA033989 data highlight potential progress in CALR-mutated myelofibrosis and essential thrombocythemia treatment.
Pharma & Biotech

Why Incyte INCA033989 could reshape essential thrombocythemia and myelofibrosis care

Find out how Incyte INCA033989 data could reshape CALR-mutated myelofibrosis and essential thrombocythemia treatment.

Read More
Incyte secures European approval for retifanlimab combo in advanced anal cancer
Pharma & Biotech

How Incyte’s retifanlimab approval could reshape first-line therapy for advanced anal cancer in Europe

European regulators approve retifanlimab for advanced anal cancer. Discover what this means for immunotherapy treatment strategies in rare oncology today.

Read More
Representative image illustrating lymphoma research and combination chemotherapy, relevant to emerging first-line DLBCL treatments like tafasitamab plus R-CHOP.
Pharma & Biotech

Incyte’s tafasitamab clears pivotal trial in high-risk DLBCL—will it shift front-line treatment?

Incyte Corporation has announced positive topline results from its Phase 3 frontMIND trial evaluating tafasitamab (marketed as Monjuvi/Minjuvi) and lenalidomide in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint of progression-free survival (PFS) and a key secondary endpoint of event-free survival (EFS), setting the stage for

Read More